Objective: To examine prescription Food and Drug Administration (FDA) C, D and X drugs in general obstetric population.
Introduction
The use of prescription drugs during pregnancy has become a concern since the discovery of birth defects resulting from thalidomide in human pregnancy in 1960s. 1, 2 Information on the safety of marketed drugs for pregnant women is limited. Clinical trials of drugs normally excluded pregnant women because of ethical and legal concerns. To guide safe drug use during pregnancy, the Food and Drug Administration (FDA) of the United States has developed a scheme to rate the potential fetal risk of drugs that are classified into one of five major categories A, B, C, D and X. 3 Most drugs are classified into category C, which includes a statement that the drug should be given only if potential benefits outweigh potential risks to the fetus. Categories D and X indicate evidence of risk in pregnancy.
The objective of the present study was to examine the patterns of pregnancy exposure to FDA category C, D and X drugs, using the population-based health services databases in the Canadian province of Saskatchewan.
Methods

Study population
This study was based on the linked maternal-infant database from the Canadian province of Saskatchewan. Details of the dataset have been described elsewhere. 4 About 18% of Saskatchewan infants who were born to mothers with registered Indian status were excluded from the study because drug information was not available for them, and women with less than 1 year of Saskatchewan Health coverage were also excluded. All live births and stillbirths born to Saskatchewan residents between 1 January 1997 and 31 December 2000 were identified. Women with one or more infants born during the study period were assigned index dates corresponding to the birth date of each qualifying infant. A random sample (by mother's provincial health-care number) of approximately 50% of the eligible women during the period of interest was selected.
Ascertainment of pregnancy drug exposure Ascertainment of prescription FDA CDX drugs during pregnancy was determined using information in the outpatient prescription drug database. FDA CDX drugs were assigned by comparing the FDA list with the available Saskatchewan Formulary for the study period. Pregnant women with at least one prescription FDA CDX drugs dispensed during pregnancy were considered as exposed. The pregnancy period of drug exposure was calculated based on the combination of gestational age, date of delivery and drug dispense date. Only FDA CDX drugs dispensed during pregnancy was counted and according to the dispense date, the exposure was further divided into three trimesters based on the estimated gestational age at the time of dispensing (first trimester: 0-12 weeks of gestation; second trimester: 13-26 weeks of gestation; third trimester: 27 weeks of gestation to delivery). Information on maternal and neonatal characteristics such as age, plurality (that is, number of fetuses of this pregnancy), parity (based on numbers of live births and stillbirths) and social assistance plan status were obtained from the provincial population registry and birth registration files. Chronic disease status was based on a chronic disease score calculated using outpatient prescription drug data in the year prior to the index date following previously established methods. 5 
Statistical analysis
We first described the maternal and fetal characteristics of the study population. We then calculated the rates and 95% confidence intervals (CIs) of exposure to FDA CDX drugs during the entire pregnancy and in each trimester of the pregnancy. We finally listed the top 10 FDA CDX drugs used during pregnancy. All analyses were performed by SAS 9.1.3(SAS Institute Inc., Cary NC, USA).
Results
A total of 18 575 pregnant women were included in the final analysis. Majority of pregnant women were 25 years of age or older with no chronic health problem and were not on provincial social assistance plan (Table 1) .
Of the 18 575 women studied, 3604 (19.4%) were dispensed FDA CDX drugs at least once during pregnancy, and the rate of exposure was higher in the first trimester (11.2%) than those in the second (7.3%) and third trimesters (8.2%). The rate of pregnancy exposure was higher for category C (15.8%) than those in category D (5.2%) or category X drugs (3.9%), with similar CDX distribution pattern for trimester-specific exposures ( Table 2) .
The most commonly dispensed category C drugs were salbutamol (or albuterol, 4.2%), trimethoprim/sulfamethoxazole (or co-trimoxazole, 3.2%), fluticasone (2.4%), codeine (2.3%) and beclomethasone (1.6%) ( Table 3 ). The most commonly dispensed Table 4 ). The most frequently dispensed category X drugs were oral contraceptives such as ethinyl estradiol/norgestrel (1.5%), ethinyl estradiol/norgestimate (0.6%) and medroxyprogester (0.5%) ( Table 5) .
Comment
Our population-based study found that about one in every five pregnant women was dispensed one or more FDA category C, D or X drugs during pregnancy. The exposure was higher in the first trimester (11.2%) than those in the second (7.3%) and third trimesters (8.2%). We also found that exposure to category C drugs (15.8%) was higher as compared to categories D (5.2%) or X drugs (3.9%), with similar CDX distribution pattern for trimester-specific exposures.
The most frequent category C drugs used in pregnancy were antiasthmatic (for example, salbutamol, fluticasone, beclomethasone), antibiotics (for example, trimethoprim/ sulfamethoxazole) and pain killers (for example, codeine). The most commonly dispensed category D drugs during pregnancy were nonsteroid anti-inflammation drugs (for example, ibuprofen and naproxen), antianxiety (for example, lorazepam), antidepressants (for example, amitriptyline) and antibiotics (for example, doxycycline). The most frequently dispensed category X drugs during pregnancy were oral contraceptives such as ethinyl estradiol/norgestrel, ethinyl estradiol/norgestimate and medroxyprogesterone.
Previous studies reported a great deal of variation in the rates of pregnancy exposure to prescription drugs with potential fetal risk. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Major differences in study design, study population, time period, drug exposure ascertainment method and drug classification systems (some used FDA system while others used European or Australian or 'ad hoc' system) make it difficult to reconcile rates observed in different studies. For studies used similar methodology, the results were quite similar to ours. For example, by linking three nationwide registration databases in Finland, Malm et al. 10 found that 20.4% women used at least one prescription drug during pregnancy with potential fetal risk and 3.4% used at least one clearly harmful drug by FDA criterion. Andrade et al. 7 reported that 1.1% of women received a category X drug after the initial prenatal care visit, and 3.3% of women received FDA category D or X during the pregnancy period, 8 using data from a Health Maintenance Organization. Olesen et al. 15 found 0.9% of Danish pregnant women filled prescriptions for drugs associated with human malformations in a population-based study. Using a survey of the record of the French Health Insurance Service of drug prescriptions, Lacroix et al. 11 reported that 1.6% of women received one or more prescriptions of drugs from FDA category X during pregnancy. Hardy et al.
14 found that 0.6% women were prescribed with one or more category X prescriptions 
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in an approximately early pregnancy using the UK General Practice Research Database. Riley et al. 13 reported that 4% of women were prescribed a category D or X drugs and the most common classes of medications prescribed were antibiotics (62%), analgesics (18%), asthma medications (18%) and antiemetics (17%). Garriguet analyzed several national databases in Canada, including the 1994/1995 through 2002/2003 National Longitudinal Survey of Children and Youth, the 2003 Canadian Community Health Survey and the 1996/1997 National Population Health Survey, and estimated that 27% of Canadian women were taking prescription medications while in pregnancy. 16 However, in this Canadian study, the author did not attempt to classify prescription drugs by fetal risk.
Our study has several strengths as compared with previous studies that have examined the issue. Since our study was based on a 50% random sample of the population eligible for drug benefits in the Canadian province of Saskatchewan, no selection bias could occur. Drug exposure information was abstracted from the outpatient prescription drug database instead of relying on women's recall, thereby avoiding recall bias. Finally, in our study, drug exposure time was determined by actual gestation period at the date of drug dispensing, so that the exposure time can be estimated precisely.
Our study also has several limitations. We used administrative data and this type of data is prone to certain degree of coding errors. 17 We have no compliance information in Saskatchewan's prescription drug file. Some patients who got prescription drugs from the pharmacy but did not actually consume them could be misclassified as exposed, and thus the exposure could be overestimated. We have not been able to take measures to deal with the potential problems caused by coding errors and noncompliance. The interpretation of the results is based on the opinion of the medical necessity of these drugs, rather than any direct, objective evidence of harm based on these exposures. Moreover, since the cohort was identified based on live births or stillbirths, by definition any pregnancies that were terminated due to fetal anomalies were excluded. Therefore, the pregnancies that continued were those with the less likelihood of harm based on these drug exposures.
Our study findings, based on a 50% random sample of the entire population in a Canadian province, suggested that one in every five pregnant women was exposed to prescription drugs with real or potential fetal risk. Many of these drugs used may be needed, because the mother's condition may be deteriorated if left untreated, and because the outcomes in infants born to mothers with untreated maternal diseases may be worse. However, under many other circumstances, the use of prescription drugs with real or potential fetal risk could be avoided or reduced. For example, our study found that trimethoprim/sulfamethoxazole is the most frequently used antibiotics in pregnancy. While antibiotics during pregnancy are often needed (for example, for urinary tract infection), 18 the use of trimethoprim/sulfamethoxazole could be avoided because it is not the only choice of antibiotics for urinary tract infection; there are alternative antibiotics with equal effects. 19 Trimethoprim/sulfamethoxazole is a folic acid antagonist that may cause birth defects and other adverse outcomes in the infants. 20, 21 Antiasthmatic drugs (category C drugs) were also frequently used. Previous studies have demonstrated that asthmatic pregnant women with asthma were at substantially increased risk for many adverse pregnancy outcomes. 22, 23 Pharmacological therapy for asthma is often necessary during pregnancy. However, an increase in the risk of congenital malformation associated with the use of certain antiasthmatic drugs such as salbutamol during pregnancy has been observed, 24 suggesting the need to choose less toxic antiasthmatic drugs even if pharmacological therapy for asthmatic mother is indicated. Antidepressants in pregnancy such as selective Patterns of prescription drugs in pregnancy SW Wen et al serotonin reuptake inhibitors (SSRIs) are other examples. Our recent study found that pregnancy use of SSRIs was associated with several adverse outcomes in infants, including low birth weight, preterm birth, fetal death and seizures in newborns. 4 Although SSRIs for severe depression is needed, its use in pregnancy may have been too liberal that may have included mild depression cases or for other indications.
We found that the most frequently dispensed X drugs during pregnancy were oral contraceptives such as ethinyl estradiol/ norgestrel. Most of these drug used occurred in the first trimester, likely the results of unintended pregnancy/failed contraceptives, 25, 26 although data error and uses for other indications may account for a few cases recorded in the second and third trimesters. Oral contraceptive drug is the most commonly used method of contraception in North America and failure of oral contraceptive pills contributes for a large proportion of unintended pregnancy. 26 Measures aimed at reducing failure of oral contraception and monitoring outcomes in pregnancies as the result of failed oral contraception should be implemented, particularly in teenagers, women with low socioeconomic status and women in unstable sexual relationships. 27 Detailed description of the patterns of pregnancy exposure to prescription drugs with real or potential fetal risk, including rate of exposure during different periods of gestation and specific drugs or drug groups, such as the one in the current study, can increase the awareness of physicians and new mothers, so that appropriate measures such as better pregnancy planning and improved communication between physician and women at reproductive age, can be employed. Further efforts directed to develop data on the safety of drugs during pregnancy are needed. The current study implies that drug use in pregnant women should be monitored and health-care providers and women must be made aware of the medications on the real or potential risks to the fetus. Patterns of prescription drugs in pregnancy SW Wen et al
